Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Taho Pharmaceuticals's selling, general, & admin. expense for the
six
months ended in Jun. 2026 was NT$32.35 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2026 was NT$52.31 Mil.
Taho Pharmaceuticals (ROCO:6467) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Taho Pharmaceuticals Selling, General, & Admin. Expense Related Terms
Taho Pharmaceuticals Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for Taho Pharmaceuticals's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taho Pharmaceuticals Selling, General, & Admin. Expense Chart
ROCO:6467 vs ZTS: Selling, General, & Admin. Expense Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Taho Pharmaceuticals's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taho Pharmaceuticals Selling, General, & Admin. Expense vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Taho Pharmaceuticals's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Taho Pharmaceuticals's Selling, General, & Admin. Expense falls into.
Taho Pharmaceuticals Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$52.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of NT$52.31 Mil mean?
Taho Pharmaceuticals (ROCO:6467) has a Selling, General, & Admin. Expense of NT$52.31 Mil as of Jun. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Taho Pharmaceuticals and its competitors.
Is Taho Pharmaceuticals' Selling, General, & Admin. Expense too high?
Taho Pharmaceuticals' current Selling, General, & Admin. Expense is NT$52.31 Mil. Overall, Taho Pharmaceuticals has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Taho Pharmaceuticals' Selling, General, & Admin. Expense compare to ZTS?
Taho Pharmaceuticals' Selling, General, & Admin. Expense of NT$52.31 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Drug Manufacturers company?
A good Selling, General, & Admin. Expense depends on the Drug Manufacturers industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Taho Pharmaceuticals and its competitors. Taho Pharmaceuticals's current Selling, General, & Admin. Expense is NT$52.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taho Pharmaceuticals stock overvalued right now?
Taho Pharmaceuticals (ROCO:6467) has a current Selling, General, & Admin. Expense of NT$52.31 Mil. The current Selling, General, & Admin. Expense is NT$52.31 Mil. Taho Pharmaceuticals' overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Taho Pharmaceuticals (ROCO:6467), the current Selling, General, & Admin. Expense is NT$52.31 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Taho Pharmaceuticals Ltd is a Taiwan based company focused on identifying and developing new products that offer therapeutic options to patient populations that may be under served. It offers a transdermal delivery platform that allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. Its transmucosal delivery system delivers the drug as a thin film, an evolution from tablets or capsules. The company is conducting research and development of multiple new drugs using two different drug delivery platform technologies: transdermal and transmucosal.
40GF Score
Get the complete analysis for ROCO:6467
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6467 has been successfully added to your 
